Biotech Stock News 3/20

$Annovis Bio(ANVS.US)$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US)$ 14% Clinical programs update
$Jaguar Health(JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US)$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US)$ 0% Presentation @ ACS
$Achieve Life(ACHV.US)$ 0% Present ORCA data @ SRNT '24
$Bristol-Myers Squibb(BMY.US)$ 0% Ph3 CheckMate -9DW data
$Kazia Therapeutics(KZIA.US)$ 0% EVT801 progress update
$Cabaletta Bio(CABA.US)$ 0% Granted ODD

$XOMA Corp(XOMA.US)$ -1% M&A update
$NGM Biopharmaceuticals(NGM.US)$ -1% Presentations @ AACR '24
$Alnylam Pharmaceuticals(ALNY.US)$ -1% KARDIA-2 trial investor event
$Tonix Pharmaceuticals(TNXP.US)$ -3% Tonmya launch & manuf. update
$Valneva(VALN.US)$ -5% FY 2023 results
$Celularity(CELU.US)$ -6% Submits ODD request for PDA-002
$Entera Bio(ENTX.US)$ -7% GLP-2 tablet PK data
$Moleculin Biotech(MBRX.US)$ -14% Reverse stock split
$EVFMD -16% Improved rebate for PHEXXI
$Aquestive Therapeutics(AQST.US)$ -17% $75M public offering @ $4.50/sh
$Endo International(ENDPQ.US)$ -33% Reorganization plan confirmation